{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:16:39Z","timestamp":1762503399281},"reference-count":14,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6719,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1023\/a:1011628900089","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T05:59:33Z","timestamp":1040623173000},"page":"1151-1155","source":"Crossref","is-referenced-by-count":34,"title":["Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor"],"prefix":"10.1016","volume":"12","author":[{"given":"O.","family":"Rick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Schwella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Schubart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Schleicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1011628900089_bb0010","first-page":"215","article-title":"Germ cell tumors\u2019 Dose-intensive therapy","volume":"25","author":"Siegert","year":"1998","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011628900089_bb0015","first-page":"41","article-title":"Approaches to managing carboplatin-induced thrombocytopenia. Focus on the role of amifostine","volume":"26","author":"Budd","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011628900089_bb0020","first-page":"1457","article-title":"Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy","volume":"47","author":"Goren","year":"1987","journal-title":"Cancer Res"},{"key":"10.1023\/A:1011628900089_bb0025","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1200\/JCO.1996.14.11.2923","article-title":"Evaluation of long-term toxicity after chemotherapy for testicular cancer","volume":"14","author":"Bokemeyer","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011628900089_bb0030","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/bjc.1995.546","article-title":"Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small cell lung cancer. A randomized phase II study","volume":"72","author":"Bettich","year":"1995","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1011628900089_bb0035","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide and cisplatin-induced toxicities Results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011628900089_bb0040","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0959-8049(97)00221-9","article-title":"Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumor cells is maintained","volume":"33","author":"Taylor","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1011628900089_bb0045","first-page":"11","article-title":"Amifostine and dose-intense paclitaxel in patients with advanced malignancies","volume":"1","author":"DiPaola","year":"1998","journal-title":"Cancer Therapeut"},{"key":"10.1023\/A:1011628900089_bb0050","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/(SICI)1097-0142(19970915)80:6<1134::AID-CNCR17>3.0.CO;2-9","article-title":"Randomized trial of carboplatin plus amifostine vs. carboplatin alone in patients with advanced solid tumors","volume":"80","author":"Budd","year":"1997","journal-title":"Cancer"},{"key":"10.1023\/A:1011628900089_bb0055","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1200\/JCO.1997.15.8.2850","article-title":"Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer Results of a phase II trial","volume":"15","author":"Tannehill","year":"1997","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1023\/A:1011628900089_bb0060","first-page":"161","article-title":"Blood progenitor cell mobilization with paclitaxel (Taxol\u00ae) in patients with germ cell cancer (Abstr)","volume":"77","author":"Schwella","year":"1998","journal-title":"Ann Hematol"},{"key":"10.1023\/A:1011628900089_bb0065","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1200\/JCO.2001.19.1.81","article-title":"Salvage treatment with paclitaxel, ifosfamide and cisplatin (TIP) plus high-dose carboplatin, etoposide and thiotepa (CET) followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer","volume":"19","author":"Rick","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011628900089_bb0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.1994.12.6.1223","article-title":"High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I \u2013 II study. The German Testicular Cancer Cooperative Study Group","volume":"12","author":"Siegert","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011628900089_bb0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","article-title":"Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer","volume":"17","author":"Gelmon","year":"1999","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419542399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419542399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/8\/1151\/19479772\/12-8-1151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:06:43Z","timestamp":1582164403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419542399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["S0923753419542399"],"URL":"https:\/\/doi.org\/10.1023\/a:1011628900089","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}